A pilot trial of pembrolizumab plus prostatic cryotherapy for men with newly diagnosed oligometastatic hormone-sensitive prostate cancer
| Autor: | Tanya O’ Neal, Phuoc T. Tran, Carolyn Chapman, Paula J. Hurley, Charles G. Drake, Rana Harb, Steven P. Rowe, Benjamin Benzon, Emmanuel S. Antonarakis, Yelena Milman, Ashley E. Ross, Bruce J. Trock |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty prostate cancer cryoablation pembrolizumab androgen ablation therapy business.industry Urology medicine.medical_treatment 030232 urology & nephrology Cryotherapy Cryoablation Pembrolizumab medicine.disease 03 medical and health sciences Regimen Prostate cancer 0302 clinical medicine 030220 oncology & carcinogenesis Internal medicine Clinical endpoint Medicine business Adverse effect Testosterone |
| Popis: | BACKGROUND: Monotherapy with immune checkpoint inhibitors has generally been unsuccessful in men with advanced prostate cancer. Preclinical data support the notion that cryotherapy may improve immune-mediated and anti-tumor responses. The objective of this study was to assess the safety and feasibility of whole-prostate gland cryotherapy combined with pembrolizumab and androgen deprivation in men with oligometastatic hormone-sensitive prostate cancer. METHODS: This single-institution, pilot trial recruited 12 patients with newly diagnosed oligometastatic prostate cancer between 2015 and 2016. Patients underwent whole-prostate cryoablation combined with short-term androgen deprivation (eight months) and pembrolizumab (6 doses). The primary clinical endpoints were the number of patients with a PSA level of |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|